Core Insights - Adagene Inc. is set to present updated clinical data for its drug ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal Cancers Symposium on January 25, 2025 [1][2] Group 1: Clinical Study Details - The Phase 1b/2 study of ADG126 in combination with Merck's KEYTRUDA has shown efficacy at a 10 mg/kg dose, with new data to include results from a 20 mg/kg loading dose followed by 10 mg/kg [2] - The presentation will take place on January 25, 2025, from 7:00 a.m. to 7:55 a.m. Pacific Time at Moscone West, San Francisco, with the abstract number 193 [3] Group 2: Virtual Event Information - A virtual key opinion leader (KOL) event will be hosted on January 25, 2025, featuring experts discussing the treatment landscape for advanced/metastatic MSS CRC and the importance of CTLA-4 targeting [4] Group 3: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [5] - The company’s SAFEbody technology aims to improve safety and tolerability of antibody therapeutics by enabling tumor-specific targeting while minimizing off-tumor toxicity [6] - ADG126, the lead clinical program, is a masked anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment, currently in clinical studies for MSS CRC [7]

Core Insights - Adagene Inc. is hosting a virtual key opinion leader (KOL) event on January 25, 2025, to discuss the treatment landscape for advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) and the importance of CTLA-4 targeting for durable responses [1] - The event will provide updates on the Phase 1b/2 study of ADG126 (muzastotug) in combination with KEYTRUDA (pembrolizumab) for advanced/metastatic MSS CRC, which will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium [2] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [8] - The company’s SAFEbody technology aims to improve safety and tolerability of antibody therapeutics by utilizing precision masking to target tumors while minimizing toxicity to healthy tissues [9] - Adagene's lead clinical program, ADG126, is a masked anti-CTLA-4 SAFEbody currently in Phase 1b/2 studies, specifically targeting MSS colorectal cancer [10] Key Opinion Leaders - Aurélien Marabelle, MD, PhD, is an expert in oncology and immunology, leading early-phase clinical trials of cancer immunotherapies and has published over 280 peer-reviewed articles [4] - Daneng Li, MD, focuses on gastrointestinal malignancies and the development of novel therapeutics, with a strong background in medical oncology [5] - Marwan Fakih, MD, has extensive experience in gastrointestinal cancers and has led numerous clinical trials, particularly in colorectal cancer [6][7]

Exhibit 99.1 Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Improved safety and ef icacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTL ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adagene Inc. Sponsored ADR is one of 1019 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gau ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adagene Inc. Sponsored ADR is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Ra ...

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024. The poster will report results of an ongoing phase 1b/2 trial of Adagene's masked anti-CTLA-4 SAFEbody in combination with the anti-PD-1 treatment pembrolizumab. The title is: Increased Therapeuti ...

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024. The poster will report results of an ongoing phase 1b/2 trial of Adagene’s masked anti-CTLA-4 SAFEbody in combination with the anti-PD-1 treatment pembrolizumab. The title is: Increased Therapeut ...

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetings. Jefferies ...

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetings. Jefferie ...

Exhibit 1.1 Adagene Inc. American Depositary Shares Each Representing 1.25 Ordinary Shares ($0.0001 par value per Ordinary Share) SALES AGREEMENT March 29, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12 Floor New York, New York 10019 Ladies and Gentlemen: Adagene Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the "Company"), confirms its agreement (this "Agreement") with Leerink Partners LLC (the "Agent"), as follows: | --- | --- | |----------- ...